Rozanolixizumab & Biosimilar Ustekinumab Among Raft Of New Drugs Filed In EU

The European Medicines Agency’s latest list of drugs under review for potential marketing approval includes a second generalized myasthenia gravis treatment from UCB and what could become the first biosimilar version of Stelara in the EU.

CDE drug review
A new batch of drug filings are now under review in the EU • Source: Shutterstock

The European Medicines Agency has added 17 new products to its latest monthly list of medicines that are under review for potential pan-EU marketing authorization, including rozanolixizumab, aumolertinib and ustekinumab.

Rozanolixizumab is UCB’s investigational treatment for generalized myasthenia gravis (gMG). It is one of two investigational gMG treatments from...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Europe

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

  • EU Pharma Reform: What You Need to Know Now

     

    As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

  • New EU Approvals

    <p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography